** Shares of drug developer Arvinas ARVN.O fall 5.6% to $6.19, hitting all-time low
** Piper Sandler reduces price target to $24 from $67 on narrowed Vepdegestrant ESR1-mutant mBC approval; remains "overweight"
** Vepdegestrant, ARVN and Pfizer's PFE.N oral drug, failed to delay progression of breast cancer in patients with most common type of the disease in a late-stage trial last month
** Vepdegestrant only helped to extend progression-free survival in a subgroup of participants with a specific gene mutation, the company said in March
** ARVN is developing PROteolysis TArgeting Chimeras (PROTACs), which is a technique for the selective degradation of target proteins
** PROTACs are novel technology never tested in man that may fail in the clinic; ARVN's partnerships may falter and it may require additional capital - Piper Sandler
** Up to last close, stock had fallen nearly 66% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。